Request for Information: Comments on the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Draft Strategic Plan, 46000-46001 [2021-17535]
Download as PDF
<![CDATA[
46000
Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices
injury, condition, or death described in
the petition is due to factors unrelated
to the administration of the vaccine
described in the petition,’’ and
2. Any allegation in a petition that the
petitioner either:
a. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition not set forth in the
Vaccine Injury Table but which was
caused by’’ one of the vaccines referred
to in the Table, or
b. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition set forth in the
Vaccine Injury Table the first symptom
or manifestation of the onset or
significant aggravation of which did not
occur within the time period set forth in
the Table but which was caused by a
vaccine’’ referred to in the Table.
In accordance with Section
2112(b)(2), all interested persons may
submit written information relevant to
the issues described above in the case of
the petitions listed below. Any person
choosing to do so should file an original
and three (3) copies of the information
with the Clerk of the United States
Court of Federal Claims at the address
listed above (under the heading FOR
FURTHER INFORMATION CONTACT), with a
copy to HRSA addressed to Director,
Division of Injury Compensation
Programs, Healthcare Systems Bureau,
5600 Fishers Lane, 08N146B, Rockville,
Maryland 20857. The Court’s caption
(Petitioner’s Name v. Secretary of HHS)
and the docket number assigned to the
petition should be used as the caption
for the written submission. Chapter 35
of title 44, United States Code, related
to paperwork reduction, does not apply
to information required for purposes of
carrying out the Program.
Diana Espinosa,
Acting Administrator.
khammond on DSKJM1Z7X2PROD with NOTICES
List of Petitions Filed
1. James Edward Perry, Garden Grove,
California, Court of Federal Claims No:
21–1530V
2. Billy Sword, Kingsport, Tennessee, Court
of Federal Claims No: 21–1534V
3. Amanda Purdin, Hilliard, Ohio, Court of
Federal Claims No: 21–1536V
4. Eileen Arcery, Depew, New York, Court of
Federal Claims No: 21–1537V
5. Alex Dosser, Oklahoma City, Oklahoma,
Court of Federal Claims No: 21–1538V
6. Rameen Rizi, Phoenix, Arizona, Court of
Federal Claims No: 21–1544V
7. Angeline Khan on behalf of A.K.,
Hayward, California, Court of Federal
Claims No: 21–1545V
8. Veronica Mendoza, Juarez, Mexico, Court
of Federal Claims No: 21–1547V
9. Jennifer Raftery, Washington, District of
Columbia, Court of Federal Claims No:
21–1549V
VerDate Sep<11>2014
17:08 Aug 16, 2021
Jkt 253001
10. Meagan Brown Schmidt, Washington,
District of Columbia, Court of Federal
Claims No: 21–1550V
11. David Shafer, Midland, Texas, Court of
Federal Claims No: 21–1552V
12. Darcy Weidner, Sharon, Pennsylvania,
Court of Federal Claims No: 21–1554V
13. Olinda Gilmore, Universal City, Texas,
Court of Federal Claims No: 21–1556V
14. William L. Miller, Cary, North Carolina,
Court of Federal Claims No: 21–1559V
15. Erik Koonce, Doylestown, Pennsylvania,
Court of Federal Claims No: 21–1560V
16. Patricia Santiago, Chicago, Illinois, Court
of Federal Claims No: 21–1562V
17. Nicholas Politano, Phoenix, Arizona,
Court of Federal Claims No: 21–1563V
18. Laura Surface, Northfield, New Jersey,
Court of Federal Claims No: 21–1565V
19. Juanita Green, Washington, District of
Columbia, Court of Federal Claims No:
21–1566V
20. Claire Kuang, Washington, District of
Columbia, Court of Federal Claims No:
21–1567V
21. Kathleen R. McNamee, North Olmstead,
Ohio, Court of Federal Claims No: 21–
1568V
22. Katie Perette, Bridgewater,
Massachusetts, Court of Federal Claims
No: 21–1569V
23. John Wirsen, Springfield, Missouri, Court
of Federal Claims No: 21–1571V
24. Raquel Hernandez, Modesto, California,
Court of Federal Claims No: 21–1572V
25. Hannah R. Boudreau, Juliet, Tennessee,
Court of Federal Claims No: 21–1573V
26. Beverly Hales, Ashland, Texas, Court of
Federal Claims No: 21–1575V
27. William McCaughey, Warwick, Rhode
Island, Court of Federal Claims No: 21–
1576V
28. Helena Smith on behalf of A.S., Chicago,
Illinois, Court of Federal Claims No: 21–
1577V
29. William Minner, Topeka, Kansas, Court
of Federal Claims No: 21–1579V
30. Keith A. Lee, New York, New York, Court
of Federal Claims No: 21–1582V
31. Bobbi Hoodiman on behalf of T.H.,
Ridgewood, New Jersey, Court of Federal
Claims No: 21–1583V
32. Edward O. Janosko, II, Wilmington, North
Carolina, Court of Federal Claims No:
21–1584V
33. Jammie Yerks, Boscobel, Wisconsin,
Court of Federal Claims No: 21–1585V
34. Dennis L. Ericson, West Hartford,
Connecticut, Court of Federal Claims No:
21–1587V
35. Todd Seely, Washington, District of
Columbia, Court of Federal Claims No:
21–1590V
36. Kathleen Pachuki, Chicago, Illinois, Court
of Federal Claims No: 21–1591V
37. Madison Jugon, The Woodlands, Texas,
Court of Federal Claims No: 21–1592V
38. Brenda Hatten, Omaha, Nebraska, Court
of Federal Claims No: 21–1593V
39. Cristian Garcia, Boston, Massachusetts,
Court of Federal Claims No: 21–1601V
40. Robert Donchess, Blythewood, South
Carolina, Court of Federal Claims No:
21–1603V
41. Luke Kramer, Upland, California, Court of
Federal Claims No: 21–1604V
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
42. James Mease, Elkton, Maryland, Court of
Federal Claims No: 21–1605V
43. Taylor Williams, Greensboro, North
Carolina, Court of Federal Claims No:
21–1606V
44. Frank Burke, Portland, Oregon, Court of
Federal Claims No: 21–1607V
45. Paul Pellegrino on behalf of A.P.,
Matthews, North Carolina, Court of
Federal Claims No: 21–1608V
46. Victoria A. Van Voorhis, Rochester, New
York, Court of Federal Claims No: 21–
1610V
47. Edna Fowler on behalf of The Estate of
William Fowler, Deceased, Dublin, Ohio,
Court of Federal Claims No: 21–1611V
48. Morgan Smith, Rock Hill, South Carolina,
Court of Federal Claims No: 21–1613V
49. Roger Nyhuis, Cincinnati, Ohio, Court of
Federal Claims No: 21–1615V
50. Julia Seeli on behalf of P.S., Phoenix,
Arizona, Court of Federal Claims No: 21–
1616V
51. Michelle Foster on behalf of H.F.,
Phoenix, Arizona, Court of Federal
Claims No: 21–1617V
52. Nicholas Delaney and Krystal Delaney on
behalf of C.M.D., St. Cloud, Minnesota,
Court of Federal Claims No: 21–1620V
53. Cassie Malone, Casper, Wyoming, Court
of Federal Claims No: 21–1625V
54. Sarah Lukas, Phoenix, Arizona, Court of
Federal Claims No: 21–1627V
55. Jeanne M. Quattromani, Westerly, Rhode
Island, Court of Federal Claims No: 21–
1628V
56. Linda Waxman, Lyndhurst, Ohio, Court
of Federal Claims No: 21–1631V
57. John D. Slusser, Jr., St. Christiansburg,
Virginia, Court of Federal Claims No: 21–
1636V
58. Julia Seeli on behalf of S. H., Phoenix,
Arizona, Court of Federal Claims No: 21–
1637V
59. Yvonne Romo, Seattle, Washington, Court
of Federal Claims No: 21–1638V
[FR Doc. 2021–17557 Filed 8–16–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information: Comments on
the National Institute of Diabetes and
Digestive and Kidney Diseases
(NIDDK) Draft Strategic Plan
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This Request for Information
(RFI) is intended to seek feedback from
the public on the draft National Institute
of Diabetes and Digestive and Kidney
Diseases (NIDDK) Strategic Plan for
Research. NIDDK invites input from:
The scientific research community;
patients and caregivers; health care
providers and health advocacy
organizations; scientific and
SUMMARY:
E:\FR\FM\17AUN1.SGM
17AUN1
Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices
professional organizations; federal
agencies; and other stakeholders,
including interested members of the
public. Organizations are strongly
encouraged to submit a single response
that reflects the views of their
organization and their membership as a
whole.
DATES: Comments must be received by
11:59:59 p.m. (ET) on August 31, 2021
to ensure consideration.
ADDRESSES: All comments must be
submitted electronically on the
submission website, available at https://
rfi.grants.nih.gov/?s=60fef9beab
43000053007ed2.
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Please direct all inquiries to: Lisa
Gansheroff, NIDDKstrategicplan@
nih.gov, 301–496–6623.
SUPPLEMENTARY INFORMATION: This
Notice is in accordance with the 21st
Century Cures Act, NIH institutes are
required to regularly update their
strategic plans. The NIDDK’s ongoing
Institute-wide strategic planning process
will develop a broad vision for
accelerating research into the causes,
prevention, and treatment of diseases
and conditions within the Institute’s
mission. This overarching trans-NIDDK
Strategic Plan will complement
NIDDK’s disease-specific planning
efforts. The Strategic Plan will have a 5year time horizon but will also include
planning for longer term efforts that
could be initiated within this time
frame.
External input has been integral to the
strategic planning process. NIDDK
established a Working Group of Council,
comprised of 44 external scientists and
patient advocates, including a subset of
the members of NIDDK’s Advisory
Council and others with expertise across
the range of NIDDK’s mission areas. The
Institute also invited broad external
input with a public RFI in 2020, and
received valuable comments from
organizations, individual researchers,
people living with diseases in NIDDK’s
mission, and others. Based on input
from the Working Group, the previous
RFI, and Council, the Institute has
prepared a draft of the Strategic Plan;
the draft will be available for public
comment through August 31, 2021 via
the new RFI at the link above.
NIDDK is committed to empowering a
multidisciplinary research community;
engaging diverse stakeholders; and
leveraging discoveries of connections
among diseases across NIDDK’s mission
to improve prevention, treatment, and
health equity—pursuing pathways to
health for all. This theme is addressed
throughout the draft strategic plan.
VerDate Sep<11>2014
17:08 Aug 16, 2021
Jkt 253001
The draft Strategic Plan includes five
major sections:
• Advance understanding of
biological pathways and environmental
contributors to health and disease
• Advance pivotal clinical studies
and trials for prevention, treatment, and
cures in diverse populations
• Advance research to disseminate
and implement evidence-based
prevention strategies and treatments in
clinics and community settings, to
improve the health of all people, more
rapidly and more effectively
• Advance stakeholder engagement—
including patients and other
participants as true partners in research
• Promote efficient and effective ways
to serve as a trusted steward of public
resources and support research for
diseases across our mission
NIDDK invites comments on the draft
Strategic Plan from: The scientific
research community; patients and
caregivers; health care providers and
health advocacy organizations; scientific
and professional organizations; federal
agencies; and other stakeholders,
including interested members of the
public. Organizations are strongly
encouraged to submit a single response
that reflects the views of their
organization and membership as a
whole.
Responses to this RFI are voluntary
and may be submitted anonymously.
Please do not include any information
that you do not wish to make public.
Proprietary, classified, confidential, or
sensitive information should not be
included in your response. The
Government will use the information
submitted in response to this RFI at its
discretion. Individual feedback will not
be provided to any responder. The
Government reserves the right to use
any submitted information on public
websites, in reports, in summaries of the
state of the science, in any possible
resultant solicitation(s), grant(s), or
cooperative agreement(s), or in the
development of future funding
opportunity announcements. This RFI is
for informational and planning purposes
only and is not a solicitation for
applications or an obligation on the part
of the Government to provide support
for any ideas identified in response to
it. Please note that the Government will
not pay for the preparation of any
information submitted or for use of that
information. NIDDK looks forward to
your input and we hope that you will
share this RFI with your colleagues.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
46001
Dated: August 11, 2021.
Bruce Tibor Roberts,
Health Science Policy Analyst, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of
Health.
[FR Doc. 2021–17535 Filed 8–16–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Clinical Trials and
Comparative Effectiveness Studies.
Date: August 23, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892,
(301) 435–6033, rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 11, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–17559 Filed 8–16–21; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\17AUN1.SGM
17AUN1
]]>Agencies
[Federal Register Volume 86, Number 156 (Tuesday, August 17, 2021)]
[Notices]
[Pages 46000-46001]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17535]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information: Comments on the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) Draft Strategic Plan
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This Request for Information (RFI) is intended to seek
feedback from the public on the draft National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) Strategic Plan for Research.
NIDDK invites input from: The scientific research community; patients
and caregivers; health care providers and health advocacy
organizations; scientific and
[[Page 46001]]
professional organizations; federal agencies; and other stakeholders,
including interested members of the public. Organizations are strongly
encouraged to submit a single response that reflects the views of their
organization and their membership as a whole.
DATES: Comments must be received by 11:59:59 p.m. (ET) on August 31,
2021 to ensure consideration.
ADDRESSES: All comments must be submitted electronically on the
submission website, available at https://rfi.grants.nih.gov/?s=60fef9beab43000053007ed2.
FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to: Lisa
Gansheroff, [email protected], 301-496-6623.
SUPPLEMENTARY INFORMATION: This Notice is in accordance with the 21st
Century Cures Act, NIH institutes are required to regularly update
their strategic plans. The NIDDK's ongoing Institute-wide strategic
planning process will develop a broad vision for accelerating research
into the causes, prevention, and treatment of diseases and conditions
within the Institute's mission. This overarching trans-NIDDK Strategic
Plan will complement NIDDK's disease-specific planning efforts. The
Strategic Plan will have a 5-year time horizon but will also include
planning for longer term efforts that could be initiated within this
time frame.
External input has been integral to the strategic planning process.
NIDDK established a Working Group of Council, comprised of 44 external
scientists and patient advocates, including a subset of the members of
NIDDK's Advisory Council and others with expertise across the range of
NIDDK's mission areas. The Institute also invited broad external input
with a public RFI in 2020, and received valuable comments from
organizations, individual researchers, people living with diseases in
NIDDK's mission, and others. Based on input from the Working Group, the
previous RFI, and Council, the Institute has prepared a draft of the
Strategic Plan; the draft will be available for public comment through
August 31, 2021 via the new RFI at the link above.
NIDDK is committed to empowering a multidisciplinary research
community; engaging diverse stakeholders; and leveraging discoveries of
connections among diseases across NIDDK's mission to improve
prevention, treatment, and health equity--pursuing pathways to health
for all. This theme is addressed throughout the draft strategic plan.
The draft Strategic Plan includes five major sections:
Advance understanding of biological pathways and
environmental contributors to health and disease
Advance pivotal clinical studies and trials for
prevention, treatment, and cures in diverse populations
Advance research to disseminate and implement evidence-
based prevention strategies and treatments in clinics and community
settings, to improve the health of all people, more rapidly and more
effectively
Advance stakeholder engagement--including patients and
other participants as true partners in research
Promote efficient and effective ways to serve as a trusted
steward of public resources and support research for diseases across
our mission
NIDDK invites comments on the draft Strategic Plan from: The
scientific research community; patients and caregivers; health care
providers and health advocacy organizations; scientific and
professional organizations; federal agencies; and other stakeholders,
including interested members of the public. Organizations are strongly
encouraged to submit a single response that reflects the views of their
organization and membership as a whole.
Responses to this RFI are voluntary and may be submitted
anonymously. Please do not include any information that you do not wish
to make public. Proprietary, classified, confidential, or sensitive
information should not be included in your response. The Government
will use the information submitted in response to this RFI at its
discretion. Individual feedback will not be provided to any responder.
The Government reserves the right to use any submitted information on
public websites, in reports, in summaries of the state of the science,
in any possible resultant solicitation(s), grant(s), or cooperative
agreement(s), or in the development of future funding opportunity
announcements. This RFI is for informational and planning purposes only
and is not a solicitation for applications or an obligation on the part
of the Government to provide support for any ideas identified in
response to it. Please note that the Government will not pay for the
preparation of any information submitted or for use of that
information. NIDDK looks forward to your input and we hope that you
will share this RFI with your colleagues.
Dated: August 11, 2021.
Bruce Tibor Roberts,
Health Science Policy Analyst, Office of Scientific Program and Policy
Analysis, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
[FR Doc. 2021-17535 Filed 8-16-21; 8:45 am]
BILLING CODE 4140-01-P
